Navigation Links
Study sheds light on angiogenesis inhibitors, points to limitations, solutions
Date:3/2/2009

glioblastomas adapt to the angiogenesis-inhibiting drugs," Bergers says. "Scientists have reported results from a clinical trial in which a subset of patients developed tumor recurrence at many sites during the course of treatment with bevacizumab, an angiogenesis inhibitor. The recurrence was measured by MRI imaging."

"While anti-angiogenesis drugs are in general not proving to be an enduring success, this does not mean they aren't valuable therapies," she adds. "There is growing evidence that the drugs improve the quality of life, or even provide increased survival typically of a few months for glioblastoma patients. The drugs also can reduce edema in brain tumors and in some instances restore memory and speech."

A tumor's resistance to angiogenesis inhibitors differs from resistance to chemotherapy drugs, Bergers explains. The targets of anti-angiogenic therapy are normal cells that form the tubes of blood vessels, known as endothelial cells. Despite the fact that the drugs are still effective against these cells, resistance develops because the tumor finds additional pathways to circumvent the drug's inhibitory effect. One evasive tumor strategy involves tapping growth factors in the body other than VEGF for the new blood vessel growth they need. If the tumor can't rebuild its vasculature to a sufficient level, it can adopt another strategyto spread and become invasive.

In contrast, tumor cells resist chemotherapy by cell-intrinsic mechanisms such as mutating the gene targeted by the drug, or changing how the tumor takes up or expels the drug.

One class of anti-angiogenesis drugs works by blocking the action of an essential protein known as vascular endothelial growth factor, or VEGF, which normally stimulates new blood vessel growth. The strategy of starving tumors by depriving them of nutrients and oxygen in blood was first proposed in the early 1970s by the late Dr. Judah Folkman at Harvard Medical School. The idea took
'/>"/>

Contact: Jennifer O'Brien
jobrien@pubaff.ucsf.edu
415-476-2557
University of California - San Francisco
Source:Eurekalert  

Page: 1 2 3 4

Related medicine news :

1. Thomson Reuters Study Tracks Impact of Recession on Hospitals
2. Insulin drug study shows significant improvements in more than 52,000 diabetic patients
3. Common Approaches to Member Retention by Health Insurance Plans are Ineffective, New Study Shows
4. Study Showing Improved Virologic Response with Nitazoxanide in Chronic Hepatitis C Published in Gastroenterology
5. TV viewing before the age of 2 has no cognitive benefit, study finds
6. Kaiser Permanente Study Finds Drinking Wine May Lower Risk of Barretts Esophagus, Precursor to Nations Fastest Growing Cancer, Esophageal Cancer
7. Snowblower Hand Injuries Often Extensive, Study Finds
8. UIC receives $3 million to study prostate cancer risk factors
9. NYU Langone Medical Center study shows that cochlear implant surgery is safe for the elderly
10. Many faces of diabetes in American youth: The SEARCH for diabetes in youth study
11. Atkins Responds to Recent New England Journal of Medicine Weight-Loss Diets Study Results
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Study sheds light on angiogenesis inhibitors, points to limitations, solutions
(Date:7/28/2015)... ... July 28, 2015 , ... According to WFTV on ... the lead among heroin toxicity cases. According to recent statistic Orlando suffers at least ... known as a hub of heroin, and law enforcement officials are struggling to keep ...
(Date:7/28/2015)... ... 2015 , ... Safeguard Scientifics, Inc. (NYSE:SFE) (“the Company”) today ... time and depending on market conditions, to repurchase shares of its outstanding common ... made in open market or privately negotiated transactions in compliance with Securities and ...
(Date:7/28/2015)... ... , ... Every summer, the public is reminded to leave the Fourth of ... their own neighborhoods. Unfortunately, according to a recent report issued by the U.S. Consumer ... " Eye Injuries Caused by Fireworks Doubled in Last 3 Years ," the number ...
(Date:7/28/2015)... CA (PRWEB) , ... July 28, 2015 , ... ... Water line has won the 2015 NCW Eco-Excellence Award for the Nutrition Beverage ... and pet lifestyle industries and elevate companies that stand out for their social ...
(Date:7/28/2015)... ... July 28, 2015 , ... Maryland Brain & Spine has adopted a new ... more service offerings, updated treatment techniques, and additional state-of-the art online resources for patients. ... invasive surgical treatment of brain and spine conditions. , “Adding the word ‘pain’ ...
Breaking Medicine News(10 mins):Health News:Heroin Overdose Deaths Increase by 270 Percent, Orlando Takes the Lead 2Health News:Heroin Overdose Deaths Increase by 270 Percent, Orlando Takes the Lead 3Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 2Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 3Health News:Carlsbad Ophthalmologist Discusses Doubling of Fireworks Eye Injuries in Three Year Span 2Health News:Carlsbad Ophthalmologist Discusses Doubling of Fireworks Eye Injuries in Three Year Span 3Health News:Coco Libre Wins 2015 NCW Eco-Excellence Award 2Health News:Maryland Brain & Spine Announces New Specialty, New Name 2Health News:Maryland Brain & Spine Announces New Specialty, New Name 3Health News:Maryland Brain & Spine Announces New Specialty, New Name 4
... LOS ANGELES, May 29 Writers and producers,from ... others were honored,at the 2008 Voice Awards last ... Administration (SAMHSA), hosted by award-winning actor and,mental health ... at Paramount Studios in Los Angeles., Winners ...
... ALOKA announced today new compact,ProSound ultrasound Systems which ... Federation of Societies for Ultrasound in Medicine and ... in Timisoara, Romania. The ProSound 2 is a,portable ... functions. High image quality technologies developed for,the premium ...
... The gene that allows fireflies to flash is helping ... UT Southwestern Medical Center researchers are among the first to ... used to determine the effectiveness of cancer drugs that choke ... requires a substrate called luciferin to be added to the ...
... More northern women feel bloating and,gurgling than their southern ... it at any one time, according to a TNS ... and Yorkshire and Humberside fared the,worst (71%), with Greater ... bloated feelings. And 61% of British women experience feeling,bloated, ...
... receiving the necessary symptom management that they require to ... its treatment, or both, according to a leading professor ... million people around the world (10 million in the ... newly diagnosed with cancer can expect to live at ...
... July 10 Cash Dividend ... - Preliminary Proxy Results, WALNUT CREEK, Calif., May 28 ... and the,preliminary proxy results at its 2008 Annual Meeting of Stockholders., ... dividend on common shares of $0.14 per share payable July,10, 2008 to ...
Cached Medicine News:Health News:SAMHSA Honors 'The Sopranos,' 'Monk,' 'Dirt' at Star-Studded Voice Awards in Los Angeles 2Health News:SAMHSA Honors 'The Sopranos,' 'Monk,' 'Dirt' at Star-Studded Voice Awards in Los Angeles 3Health News:SAMHSA Honors 'The Sopranos,' 'Monk,' 'Dirt' at Star-Studded Voice Awards in Los Angeles 4Health News:ALOKA to Unveil a New Compact 'ProSound' Diagnostic Ultrasound System 2Health News:Fireflies' glow helps UT Southwestern researchers track cancer drug's effectiveness 2Health News:Fireflies' glow helps UT Southwestern researchers track cancer drug's effectiveness 3Health News:North South Divide Exists in UK Digestive Health 2Health News:North South Divide Exists in UK Digestive Health 3Health News:Cancer survivors are living 'in limbo' with unmet needs for care 2Health News:Cancer survivors are living 'in limbo' with unmet needs for care 3Health News:Longs Drug Stores Corporation Announced at Its Annual Meeting of Stockholders 2
(Date:7/28/2015)... FORT WORTH, Texas , July 28, 2015 /PRNewswire/ ... Report "Global Dermatology Devices Market by Type (Dermatology Treatment ... MRI, CT), Dermatoscopes, Microscopes]), by Application, by Geography - ... market is expected to reach $11.88 billion by 2019, ... Browse through the TOC of Global Dermatology ...
(Date:7/28/2015)... , July 28, 2015 Research ... addition of the "Global Hearing Aids Market ... The global hearing aids market to grow ... 2014-2019. Factors such as changing ... driving market growth. The market has witnessed immense ...
(Date:7/28/2015)... 2015   CSL Behring announced today ... Authorization Application (MAA) for the company,s investigational long-acting ... recombinant albumin (rIX-FP) for the prophylaxis and treatment ... Upon Swissmedic approval, rIX-FP will provide hemophilia B ... intervals up to 14 days. ...
Breaking Medicine Technology:Global Dermatology Devices Market to be Worth $11.88 Billion by 2019 2Global Dermatology Devices Market to be Worth $11.88 Billion by 2019 3Global Hearing Aids Market 2015-2019 with G N Store Nord, Sonova Holdings & William Demant Dominating 2Swissmedic Accepts for Review CSL Behring's MAA for rIX-FP for Patients with Hemophilia B 2Swissmedic Accepts for Review CSL Behring's MAA for rIX-FP for Patients with Hemophilia B 3Swissmedic Accepts for Review CSL Behring's MAA for rIX-FP for Patients with Hemophilia B 4
... Phosphagenics,Limited (ASX: POH, AIM: PSG, OTCQX: PPGNY) today ... undertake a Phase 1 transdermal,oxycodone clinical trial aimed ... management product. Phosphagenics has submitted all necessary ... be conducted at CMAX - an independent clinical ...
... Phase 2 clinical development, PRINCETON, N.J., Sept. ... in the discovery and development of novel,small molecule ... 2a,clinical study of PS433540, the company,s lead internal ... receptor antagonist,(DARA) that is being developed as a ...
Cached Medicine Technology:Phosphagenics to Conduct a Phase 1 Transdermal Oxycodone Clinical Trial 2Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 2Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 3Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 4Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 5
... Intelli-Storeroom™ was developed to create physically secured ... and exits are converted to RFID portals. ... readers and antennas by VerdaSee's Field Engineering ... to assets that are to be tracked. ...
... Mobile Aspects provides hospitals ... products to track all their ... Our RFID systems remove all ... items and people accurately. iRIS, ...
The WatchMate LC model is a cost-effective solution for monitoring a single exit, and provides local notification of an alarm....
... AgileTrac Surgical Services is a Web-based ... to track, manage, and measure patient flow ... process, from admission to discharge. AgileTrac collects ... of care delays your patient might experience. ...
Medicine Products: